Intellia Therapeutics, Inc. (NTLA) on Monday reported positive topline results from its Phase 3 HAELO trial of lonvo-z, a CRISPR-based gene editing therapy for Hereditary angioedema (HAE). The study met its primary goal.
HAE is a rare genetic condition in which patients experience recurrent and potentially life-threatening swelling attacks in various parts of their body.
Results showed a one-time infusion of lonvo-z cut attack rates by 87% versus placebo over six months, with monthly attacks averaging 0.26 compared with 2.10 in the placebo group. The company said a significantly higher proportion of patients remained attack-free during the study period versus placebo.
Lonvo-z demonstrated a favorable safety profile, with all reported adverse events being mild to moderate.
Intellia said it has begun a rolling biologics license application submission with the U.S. Food and Drug Administration and expects a potential U.S. launch in the first half of 2027, if approved.
Shares rose more than 4% in pre-market trading after closing at $13.63 on Friday.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.